Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Non Operating Income (2020 - 2025)

Foghorn Therapeutics has reported Non Operating Income over the past 6 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Non Operating Income at $2.2 million for Q4 2025, down 50.82% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (down 24.63% YoY), and the annual figure for FY2025 was $12.1 million, down 24.63%.
  • Non Operating Income for Q4 2025 was $2.2 million at Foghorn Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Non Operating Income for FHTX hit a ceiling of $4.7 million in Q3 2024 and a floor of -$1.1 million in Q4 2021.
  • Median Non Operating Income over the past 5 years was $3.1 million (2022), compared with a mean of $2.5 million.
  • Biggest five-year swings in Non Operating Income: plummeted 5152.38% in 2021 and later surged 1275.69% in 2022.
  • Foghorn Therapeutics' Non Operating Income stood at -$1.1 million in 2021, then soared by 382.75% to $3.0 million in 2022, then rose by 11.27% to $3.3 million in 2023, then surged by 34.87% to $4.5 million in 2024, then plummeted by 50.82% to $2.2 million in 2025.
  • The last three reported values for Non Operating Income were $2.2 million (Q4 2025), $2.7 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.